544 related articles for article (PubMed ID: 19255018)
1. Do we have evidence for policy changes in the treatment of children with latent tuberculosis infection?
Lobato MN; Jereb JA; Castro KG
Pediatrics; 2009 Mar; 123(3):902-3. PubMed ID: 19255018
[No Abstract] [Full Text] [Related]
2. Latent tuberculosis infection in children: a call for revised treatment guidelines.
Finnell SM; Christenson JC; Downs SM
Pediatrics; 2009 Mar; 123(3):816-22. PubMed ID: 19255008
[TBL] [Abstract][Full Text] [Related]
3. Multidrug-resistant tuberculosis in military recruits.
Freier G; Wright A; Nelson G; Brenner E; Mase S; Tasker S; Matthews KL; Bohnker BK
Emerg Infect Dis; 2006 May; 12(5):760-2. PubMed ID: 16704832
[TBL] [Abstract][Full Text] [Related]
4. The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis.
Oxlade O; Falzon D; Menzies D
Eur Respir J; 2012 Mar; 39(3):626-34. PubMed ID: 21828030
[TBL] [Abstract][Full Text] [Related]
5. Shorter treatment duration for selected patients with multidrug-resistant tuberculosis.
Leung EC; Yew WW; Leung CC; Leung WM; Tam CM
Eur Respir J; 2011 Jul; 38(1):227-30. PubMed ID: 21719503
[No Abstract] [Full Text] [Related]
6. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
[TBL] [Abstract][Full Text] [Related]
7. [Drug resistance of Mycobacteria tuberculosis in patients with new-onset pulmonary tuberculosis].
Khudushina TA; Voloshina EP; Adamovich NV; Maslakova MG; Terekhova ND
Probl Tuberk Bolezn Legk; 2005; (12):37-9. PubMed ID: 16496762
[TBL] [Abstract][Full Text] [Related]
8. [Reasons for drug-resistant tuberculosis emergence].
Tu DH
Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jun; 30(6):403-5. PubMed ID: 17673006
[No Abstract] [Full Text] [Related]
9. The threat of multidrug resistance: is tuberculosis ever untreatable or uncontrollable?
Gleissberg V
Lancet; 1999 Mar; 353(9157):998-9. PubMed ID: 10459924
[No Abstract] [Full Text] [Related]
10. [Long-term results of treatment for drug-resistant pulmonary tuberculosis in socially adapted patients].
Khodashova ML; Iuditskiĭ MV; Semenova OV
Probl Tuberk Bolezn Legk; 2004; (3):26-8. PubMed ID: 15338896
[TBL] [Abstract][Full Text] [Related]
11. [Drug-resistant pulmonary tuberculosis at the penitentiaries].
Kononets AS
Probl Tuberk Bolezn Legk; 2008; (12):60-3. PubMed ID: 19227326
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand.
McNaughton A; Blackmore T; McNaughton H
Eur Respir J; 2016 Oct; 48(4):1256-1259. PubMed ID: 27694421
[No Abstract] [Full Text] [Related]
13. Moving forward with evidence and controversies: the challenges of MDR-TB.
Chiang CY; Van Deun A; Caminero JA
Int J Tuberc Lung Dis; 2006 Aug; 10(8):827. PubMed ID: 16898363
[No Abstract] [Full Text] [Related]
14. Outcomes of multidrug-resistant tuberculosis treatment in HIV-positive patients in New York City, 1990-1997.
Frieden TR; Munsiff SS; Ahuja SD
Int J Tuberc Lung Dis; 2007 Jan; 11(1):116. PubMed ID: 17217141
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.
Pina JM; Clotet L; Ferrer A; Sala MR; Garrido P; Salleras L; Domínguez A
Respir Med; 2013 May; 107(5):768-77. PubMed ID: 23490222
[TBL] [Abstract][Full Text] [Related]
16. [The cost of treatment in new case and multidrug resistant case in pulmonary tuberculosis].
Kizkin O; Hacievliyagil SS; Türker G; Günen H
Tuberk Toraks; 2003; 51(4):410-5. PubMed ID: 15143390
[TBL] [Abstract][Full Text] [Related]
17. Public health. Responding to market failures in tuberculosis control.
Gupta R; Kim JY; Espinal MA; Caudron JM; Pecoul B; Farmer PE; Raviglione MC
Science; 2001 Aug; 293(5532):1049-51. PubMed ID: 11463877
[No Abstract] [Full Text] [Related]
18. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis.
Gupta R; Espinal MA; Raviglione MC
Int J Tuberc Lung Dis; 2000 Nov; 4(11):1089-91. PubMed ID: 11092726
[No Abstract] [Full Text] [Related]
19. Tuberculosis treatment: dangerous regimens?
Rieder HL; Arnadottir T; Trébucq A; Enarson DA
Int J Tuberc Lung Dis; 2001 Jan; 5(1):1-3. PubMed ID: 11263509
[No Abstract] [Full Text] [Related]
20. Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
Gupta R; Raviglione MC; Espinal MA
Int J Tuberc Lung Dis; 2001 Dec; 5(12):1078-9. PubMed ID: 11769764
[No Abstract] [Full Text] [Related]
[Next] [New Search]
